CD274 and neoplasm: For instance, in patients with advanced NSCLC following treatment with PD-1 inhibitor (pembrolizumab), exome sequencing revealed that those with higher tumor neoantigen burdens and lower intra-tumor heterogeneity exhibit elevated PD-L1 expression, heightened sensitivity to immune checkpoint inhibitory therapies, and extended overall survival [162,200,201].